- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04869787
A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI (SCD PED-02)
A Multi-Center, Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) for the Treatment of Immunomodulatory Dysregulation Due to Pediatric Acute Kidney Injury (AKI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The SCD PED-02 trial is examining the safety and efficacy of the Selective Cytopheretic Device (SCD) in treating pediatric acute kidney injury (AKI). Importantly, acute kidney injury is a highly lethal condition in critically ill patients. Despite improvements in acute medical care and advances in dialysis therapies, the mortality rate during the past four decades of this condition has not improved. Critically ill patients with AKI in hospital ICU settings have mortality rates of approximately 50%, including pediatric patients. AKI promotes a systemic inflammatory response syndrome (SIRS) which results in systemic microvascular damage and, if severe, multi-organ dysfunction. Activated circulating leukocytes play a central role in this process. Leukocytes, especially neutrophils, are major contributors to the pathogenesis and progression of many inflammatory disorders, including SIRS, sepsis, ischemia reperfusion injury, and acute respiratory distress syndrome (ARDS). Many therapeutic approaches are under investigation to limit the activation and tissue accumulation of leukocytes at sites of inflammation to minimize tissue destruction and disease progression.
The SCD is comprised of tubing, connectors, and a synthetic membrane cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and it is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits. The SCD is a synthetic membrane with the ability to bind activated leukocytes and, when used in a continuous renal replacement therapy (CRRT) extracorporeal circuit in the presence of regional citrate anticoagulation, modulates inflammation.
The SCD PED-02 study will test the primary hypothesis that up to ten sequential 24-hour SCD treatments in pediatric patients with AKI will be completed safely and improve survival compared to historical controls who received CRRT alone.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Children's of Alabama
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient's parent or legal representative has provided informed consent
- Must be receiving medical care in an intensive care unit
- Age less than 18 years.
- Body weight between ≥10 and ≤ 20 kilograms
- Intent to receive full supportive care through aggressive management
- Clinical diagnosis of AKI requiring CRRT
- At least one non-renal organ failure OR presence of proven/suspected sepsis
Exclusion Criteria:
- Threshold blood pressure of 80/40 mmHg
- Patients with a solid organ transplant or those with a bone marrow or stem cell transplant in the previous 100 days or who have not engrafted
- Acute or chronic use of circulatory support device, other than extracorporeal membrane oxygenation (ECMO)
- Presence of preexisting advanced chronic renal failure on chronic renal replacement therapy or with an estimated glomerular filtration rate less than 30 mL/min/1.73m2
- AKI occurring in the setting of burns, obstructive uropathy, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, cyclosporine or tacrolimus nephrotoxicity
- Metastatic malignancy which is actively being treated or may be treated by chemotherapy or radiation during the subsequent three month period after study therapy
- Chronic immunosuppression with the exception of corticosteroids up to a dose of 10 mg of prednisone per day
- Known positive HIV or AIDS or COVID-19
- Current Do not Attempt Resuscitation (DNAR), Allow Natural Death (AND), or withdrawal of care status, or anticipated change in status within the next 7 days
- Patient not expected to survive 28 days because of an irreversible medical condition
- Any medical condition that the Investigator thinks may interfere with the study objectives
- Treating clinician does not feel it is in the best interest of the patient
- Platelet count <15,000/mm3
- Concurrent enrollment in another interventional clinical trial
- Use of any other investigational drug or device within the previous 30 days
- Use of AN-69 hemofilter membrane for CRRT
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: SCD Treatment
Pediatric patients receiving SCD + CRRT for up to 10 days
|
SCD in line with CRRT extracorporeal device
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of SCD-related Adverse Events (AE)
Time Frame: From enrollment to Day 60 post treatment
|
Total number of AEs across all participants that are considered to be at least possibly related to SCD therapy per the site investigator
|
From enrollment to Day 60 post treatment
|
Number of Unanticipated Adverse Device Effects (UADE)
Time Frame: From enrollment to Day 60 post treatment
|
Total number of UADEs across all participants treated with the SCD
|
From enrollment to Day 60 post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital Length of Stay
Time Frame: From enrollment to Day 60 post treatment
|
Total days each participant spends as an inpatient at an acute care facility
|
From enrollment to Day 60 post treatment
|
Intensive Care Unit (ICU) Length of Stay
Time Frame: From enrollment to Day 60 post treatment
|
Total days each participant spends in an ICU during the primary admission
|
From enrollment to Day 60 post treatment
|
Mortality
Time Frame: Day 28 post treatment
|
Mortality rate as a percent of all participants treated with the SCD
|
Day 28 post treatment
|
Renal Recovery
Time Frame: Day 28 post treatment
|
Percent of patients free from chronic dialysis treatments
|
Day 28 post treatment
|
Mortality
Time Frame: Day 60 post treatment
|
Mortality rate as a percent of all participants treated with the SCD
|
Day 60 post treatment
|
Renal Recovery
Time Frame: Day 60 post treatment
|
Percent of patients free from chronic dialysis treatments
|
Day 60 post treatment
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCD PED-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
University Hospital, GhentWithdrawn
-
Astellas Pharma IncCompleted
-
South Egypt Cancer InstituteCompletedAcute Kidney Injury (AKI)Egypt
-
Xuzhou Medical UniversityUnknownPostoperative Acute Kidney Injury
-
Assiut UniversityUnknownNeonatal Acute Kidney InjuryEgypt
-
Assiut UniversityUnknownPostoperative Acute Kidney Injury
-
Hospital de BaseFundação de Amparo à Pesquisa do Estado de São PauloUnknownEarly Acute Kidney InjuryBrazil
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalRecruiting
Clinical Trials on Selective Cytopheretic Device
-
Lenar YessayanSuspendedCardiorenal Syndrome | Acute on Chronic Systolic Congestive Heart FailureUnited States
-
Lenar YessayanRecruitingAcute Kidney Injury | Hepatorenal SyndromeUnited States
-
CytoPherx, IncChildren's Hospital Medical Center, Cincinnati; Innovative BioTherapies (IBT)Completed
-
Lenar YessayanSuspendedHeart Failure | Renal Failure | Chronic Systolic Heart Failure | Cardiorenal SyndromeUnited States
-
SeaStar MedicalBaim Institute for Clinical Research; MedtoxCompletedAcute Renal FailureUnited States
-
SeaStar MedicalICON plcRecruiting
-
University of MichiganRenal Research InstituteTerminatedEnd Stage Renal Disease | Acute Kidney Injury | Chronic Kidney Disease Stage 5United States
-
Belkin Laser Ltd.Horizon 2020 - European CommissionCompleted
-
Insel Gruppe AG, University Hospital BernBern University of Applied SciencesRecruiting
-
Santersus AGCompletedSepsis | Sepsis-associated AKIRussian Federation